HC Wainwright & Co. Reiterates Buy on Aytu BioPharma, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Vernon Bernardino reiterates a Buy rating on Aytu BioPharma (NASDAQ:AYTU) and maintains a $20 price target.
May 31, 2023 | 11:14 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Vernon Bernardino reiterates a Buy rating on Aytu BioPharma and maintains a $20 price target.
The reiterated Buy rating and maintained $20 price target by HC Wainwright & Co. analyst Vernon Bernardino indicates a positive outlook for Aytu BioPharma. This news is likely to have a positive short-term impact on the stock price as it shows confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100